Veradermics’ VDPHL01 Targets $135–$182 Valuation in Hair-Loss Pipeline

Veradermics (MANE) highlighted its lead candidate, VDPHL01—a first-in-class extended-release oral minoxidil tablet designed to treat pattern hair loss in both men and women. The drug, targeting androgenetic alopecia, is positioned to address a market estimated at 80 million U.S. patients, with significant unmet need in women, where no FDA-approved oral therapy exists. Clinical trials show promising early results, with top-line data from Study 302 (Phase II/III in men) expected in mid-2024, and Study 306 (female patients) slated for first-half 2027. Physician surveys indicate over 90% view VDPHL01 as differentiated, with 50% of doctors planning to prescribe it within a month of launch. Patient willingness to pay averages $100+ monthly, reflecting high willingness to adopt a new treatment despite current dissatisfaction with existing options, including Rogaine and Nutrafol supplements. Analysts project a strong upside, with price targets ranging from $135 to $182 per share, as the company prepares for its next earnings report on December 2, 2026.